Abstracts tagged "gout"

Abstract Number: 2001 • ACR Convergence 2025
Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Jason Yang¹, Ted Mikuls², Harlan Sayles², Michael Pillinger³, Jeff Newcomb², Bridget Kramer², Anne Davis-Karim⁴, Mary Brophy⁵, Ryan Ferguson⁵, Paul Palevsky⁶, James O'Dell² and Tuhina Neogi⁷, ¹Boston Medical Center, Boston, MA, ²University of Nebraska Medical Center, Omaha, NE, ³New York University Grossman School of Medicine, New York,, NY, ⁴VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁵VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁶VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Gout flares are an important treatment outcome in gout. Although flares are typically assessed by occurrence (yes/no) or a simple count in trials of…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 2002 • ACR Convergence 2025
Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Joshua Baker¹, Harlan Sayles², Chung-Chou Chang³, Brian Coburn⁴, Bryant England² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Informative censoring in epidemiologic research studies (the loss of data from the risk set that is related to the exposure and/or outcome) can cause…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Blanka Stiburkova¹, katerina pavelcova², Jana masinova³, Pavel Jesina⁴, Yu Toyoda⁵ and Tappei Takada⁵, ¹Institute of Rheumatology, Praha ¹⁰, Czech Republic, ²Institute of Rheumatology, Praha ², Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Revmatologický ústav, Praha ², Czech Republic, ⁵The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…
Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Xiao-Na Ma¹, Mei-Feng Shi¹, Qian Chen¹, Fang-Shu Zou¹, Wei Feng¹, Qing-Ping Liu¹, Chang-Song Lin¹, Nan Li², Xiao-Bao Liu¹ and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
Abstract Number: 2003 • ACR Convergence 2025
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Julia Buchfuhrer¹, Niranjan Kathe², Elizabeth Ibiloye³, Seth Kuranz⁴, Virginia Noxon-Wood⁴, Alexis Woods⁵ and Laurence Gozalo⁴, ¹JB Arthritis and Rheumatology Center, Downey, CA, ²Amgen Inc, San Diego, CA, ³Amgen Inc, Thousand Oaks, CA, ⁴Inovalon, Bowie, MD, ⁵Amgen, Detroit, MI
Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
Abstract Number: 2589 • ACR Convergence 2025
Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Yuanpiao Ni¹, Fanxin Zeng², Yufeng Qing³ and Quanbo Zhang³, ¹Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic), ²Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), ³The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…
Abstract Number: 1125 • ACR Convergence 2025
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
Brian Coburn¹, Daniel Wright², Jeff Newcomb³, Mary Brophy⁴, Anne Davis-Karim⁵, Ryan Ferguson⁴, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, Bryant England³, James O'Dell³, Lisa Stamp⁹, Ted Mikuls³ and Joshua Baker¹⁰, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Otago, Dunedin, New Zealand, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁵VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁹University of Otago, Christchurch, Christchurch, New Zealand, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…
Abstract Number: 1891 • ACR Convergence 2025
Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
Eva Kalra¹, Drumadala Gajbhiye², Chandana Tummala³ and Hardik Dineshbhai Desai⁴, ¹Trident Medical Center, North Charleston, SC, ²Government medical college Akola Maharashtra India ⁴⁴⁴⁰⁰¹, Akola, India, ³Internal Medicine, Vydehi Institute Of Medical Sciences and Research Centre, Whitefield-⁵⁶⁰⁰⁶⁶, Bangalore, Karnataka, India, Banglore, India, ⁴Ahmedabad, Gujarat, India, ³⁸²³⁵⁰, Ahmedabad, India
Background/Purpose: Gout, a chronic inflammatory arthritis driven by hyperuricemia, has become an increasingly significant cause of disability in the United States. Despite therapeutic advances, its…
Abstract Number: 2004 • ACR Convergence 2025
Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
Kanon Jatuworapruk¹, Binit Vaidya², ANA MONICA ESTRELLA³, MA. HANNA MONICA SOLLANO³, Ronaldo De Vera⁴, Ida Ayu Ratih Wulansari Manuaba⁵, Rakhma Hellmi⁶, Panchalee Satpanich⁷, Nittayawadee Aeamsaard⁸, MAHABALESHWAR MAMADAPUR⁹, Mustafa Alhayali¹⁰, Chang-Nam Son¹¹, Syahrul Sazliyana Shaharir¹², Galymzhan Togizbayev¹³ and Jose Paulo Lorenzo³, ¹Thammasat University, Pathumthani, Thailand, ²National Center for Rheumatic Diseases, Kathmandu, Nepal, ³Makati Medical Center, Makati, Philippines, ⁴Tricity Medical Center in Pasig City, Pasig, Philippines, ⁵Bali International University, Bali, Indonesia, ⁶Kariadi Hospital Medical Center, Semarang, Indonesia, ⁷Faculty of Medicine Vajira Hospital, bangkok, Thailand, ⁸Saraburi Hospital, Saraburi, Thailand, ⁹JSS MEDICAL COLLEGE AND HOSPITAL, Mysore, Karnataka, India, ¹⁰Baghdad Teaching Hospital, Baghdad, Iraq, ¹¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ¹²Universiti Kebangsaan Malaysia, Selangor, Malaysia, ¹³Qazaq College of Rheumatology, Almaty, Kazakhstan
Background/Purpose: The burden of gout is rising in low-income and middle-income countries in the Asia-Pacific region. However, individuals with gout in this region remain underrepresented…
Abstract Number: 2590 • ACR Convergence 2025
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Sharan Rai¹, Natalie McCormick², Xochitl Morgan³, Matthew Nayor⁴, Robert Terkeltaub⁵, Dylan Dodd⁶, Lama Nazzal⁷, Huilin Li⁷, Gary Curhan⁸, Curtis Huttenhower³ and Hyon K. Choi⁹, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, ⁴Boston University, Boston, ⁵Retired, San Diego, CA, ⁶Stanford University, Palo Alto, CA, ⁷NYU Langone, New York, NY, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Approximately 21% of US adults have hyperuricemia, the causal precursor for gout. Human cells do not degrade urate (due to uricase gene inactivation). However,…
Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Inna Orlova¹, Iryna Shapoval², Nataliia Shkolina¹, Nataliia Kuzminova¹ and Mykola Stanislavchuk³, ¹National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine, ²National Pirogov Memorial Medical University, Vinnytsya (Ukraine), Vinnytsya, Ukraine, ³National Pirogov Memorial Medical University, Vinnytsia, Vinnytsia, Ukraine
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].